Deep Intelligence Across Industries

Company Headquarters: Tokyo, Japan Founded: 1921 Workforce: 25,000 Company Working: Terumo Medical Corporation delivers innovative health solutions and provides breakthrough solutions and technologies. The company is involved in manufacturing and sales of medical products and equipment, such as pharmaceuticals, nutritional food supplements, disposable medical devices, vascular grafts, and blood glucose monitoring systems, among others. It has a market presence in over 160 countries in the world. It operates its business through three segments, namely, cardiac and vascular company, blood management company, and general hospital company. Terumo Interventional Systems (TIS), a division of Terumo Medical Corporation, is a market leader in minimally invasive entry site management, lesion access, and interventional technologies. TIS offers a complete, solution-based product portfolio used in advanced coronary, peripheral endovascular and urological treatments with strategic initiatives in Transradial Access, Complex Coronary Intervention, Peripheral Artery Disease and Embolotherapy.

Company Headquarters: New Jersey, US Founded: 1897 Workforce: ~65,000 Company Working: Becton, Dickinson and Company (BD) is engaged in developing and manufacturing medical supplies, laboratory equipment, and diagnostic products. It operates in two segments, BD Medical and BD Life Sciences. Its life sciences segment offers products, such as liquid-based cytology systems, specimens, and blood collection products and systems, automated blood and tuberculosis culturing, molecular testing, rapid diagnostic assays, microbiology laboratory automation products, and fluorescence-activated cell sorters. Its medical segment comprises products, such as needle-free IV connectors and extension sets, peripheral IV and advanced peripheral catheters, acute dialysis catheters, vascular care and preparation products, and IV fluids. BD has a strong presence throughout Eastern Europe, the Middle East, and Africa regions with technical specialists, sales specialists, technical service, and application support for its products. The company distributes its products in North America (Canada, Mexico, and the US), Europe (Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherland, Poland, Switzerland, Russia, United Kingdom, Turkey, Hungary, Italy), South America (Argentina, Brazil, Chile, and Colombia), Asia-Pacific (Australia, New Zealand, Indonesia, Korea, Malaysia, Philippines, Thailand, and Vietnam) and the Middle East and Africa (the Middle East, North Africa, and Africa).

Company Headquarters: Nagoya, Japan Founded: 1951 Workforce: ~3,083 Company Working: Menicon Co., Ltd (Menicon) manufactures, sells, exports, and imports contact lenses, lens care products, and other medical goods worldwide. The company offers daily disposable and replacement type lenses. Menicon is the only manufacturer in the world that is involved in all areas of contact lens-related business, including material development, lens designing, and manufacturing of contact lenses, and care solutions.

Company Headquarters: Pleasanton, California, US Founded: 1980 Workforce: ~11,800 Company Working: CooperVision is a global medical device company which manufactures soft contact lenses. The company operates through two business units, CooperVision and Coopersurgical. The company offers contact lenses in a variety of materials, which include phosphorylcholine technology (PC) and silicone hydrogel aquaform technology. It primarily manufactures its products in facilities located in the UK, Hungary, Puerto Rico, Costa Rica, and the US and distributes its products in the US, UK, Belgium, and various smaller international regions.

Company Headquarters: New Jersey, US Founded: 1853 Workforce: 20,000+ Company Working: Bausch & Lomb Incorporated develops, manufactures, and markets eye care products. The company’s products include contact lens and lens care products, such as chemical disinfectants for soft contact lenses, Boston line of products, and prescription pharmaceutical medicines to treat eye conditions such as glaucoma, conjunctivitis, eye allergies, dry eye, and retinal diseases, among others. Moreover, it also offers contract manufacturing services for sterile and non-sterile solutions, suspensions, ointments, gels, creams, nasals, and injectables. It is headquartered in the US and has additional offices in Argentina, Australia, Austria, Belgium, Bulgaria, Brazil, Canada, China, the Czech Republic/Slovakia, Dubai, France, Germany, Greece, and Hong Kong, among others. Bausch & Lomb Incorporated operates as a subsidiary of Bausch Health Companies Inc.

Acron Group — CNM

Company Headquarters: Zug, Switzerland Founded: 2001 Workforce: ~23,000 Company Working: EuroChem Group AG (EuroChem) manufactures and markets agricultural chemicals. The company produces nitrogen, phosphate, and NPK fertilizers, as well as offers feed phosphates, industrial acids, and mineral raw materials. It operates production facilities in Belgium, China, Kazakhstan, Lithuania, and Russia. It operates through 4 segments, namely, mining, fertilizers, commercial, and others. It has seven production sites for fertilizers spread across the US, Germany, Russia, and China. The sales and distribution operations of the company span across five regions: Europe, Russia/CIS, North America, Latin America, and Asia. It has an annual capacity of 350,000 tonnes of ammonia production.

Company Headquarters: Amsterdam, Netherlands Founded: 2013 Workforce: ~3,600 Company Working: OCI NV is a leading global producer and distributor of nitrogen products providing sustainable solutions to agricultural and industrial customers around the world. Its production capacity spans 4 continents and comprises approximately 16.1 million metric tons per year of nitrogen fertilizers, methanol, diesel exhaust fluid, melamine, and other nitrogen products. It operates 9 production sites globally. It operates through business segments, namely, Nitrogen Europe, Nitrogen US, Methanol US, Methanol Europe, Fertiglobe, and others. The company has started production of green ammonia in 2019 through its Dutch fertilizer complex with an annual capacity of 6.9 million metric tons. It offers ammonia under its Fertiglobe segment and sold 2.1 million metric tons of ammonia in 2019. Its fertilizer distribution infrastructure includes a wholly owned ammonia export terminal at the port of Rotterdam, warehousing capacity across the US, Europe, the Middle East and North Africa, rail car fleets in the US and Europe, and a 15 KT ammonia vessel.

Nutrien is the world's largest crop-input company by integrated scope. It combines the world's largest potash capacity with a top-tier North American nitrogen franchise, a smaller phosphate business, and the world's largest agricultural retail network, Nutrien Ag Solutions. Six Saskatchewan potash mines give it about 20% of global potash nameplate capacity (2025 AIF). Its gas-advantaged North American nitrogen plants supply ammonia, urea, ESN® and upgraded solutions to agricultural and industrial buyers. The retail network of about 1,700–1,800 locations across the US, Canada, Australia and South America sells nutrients, crop protection, seed, services and financing to roughly half a million grower accounts, with a growing proprietary-products margin layer. The investment case rests on a cost-advantaged, long-life upstream asset base, earnings that are less volatile than pure-play producers because of retail, and a 2024–2026 "simplify and focus" program. That program is exiting non-core assets (Profertil, Sinofert, Trinidad and New Madrid nitrogen, with Phosphate and Brazil retail under review) to lift free cash flow and shareholder returns. --- **Company's own description (FY2025 annual report / Q2 2026 MD&A).** Nutrien describes itself as a leading global provider of crop inputs and services. It says it operates a world-class network of production, distribution and ag retail facilities positioned to serve farmers efficiently. Its stated vision is to be the leading global agricultural solutions provider, delivering superior shareholder value through safe and sustainable operations. The strategy rests on three priorities: simplify and focus, operational excellence, and disciplined, intentional capital allocation. Management says the strategy is designed to produce low-risk, structural free-cash-flow growth and reliable, growing cash returns to shareholders. **Business model.** Nutrien is vertically integrated across the crop-nutrient value chain: **Upstream (Potash, Nitrogen, Phosphate):** mining and chemical manufacturing of the three primary crop macronutrients. In 2025 the company sold about 27.5 million tonnes of manufactured fertilizer from plants in Canada, the US and Trinidad (2025 AIF). **Midstream:** global sales, freight, transportation and distribution, reported inside each upstream segment. Offshore potash is sold exclusively through Canpotex, the export marketing joint venture Nutrien shares 50/50 with Mosaic. **Downstream (Retail / Nutrien Ag Solutions):** direct-to-grower distribution of crop nutrients, crop protection products, seed and merchandise. Retail also provides agronomy services (application, soil sampling, variable-rate prescriptions, crop monitoring by more than 4,200 crop consultants) and financing through Nutrien Financial. It manufactures about 1,700 proprietary products at eight formulation facilities. **Revenue model mix.** Nutrien is overwhelmingly a product company. Services and financing are small but higher margin. *Derived from FY2025 Q4 release segment and product-line tables. Retail product sales = 7,285 + 6,105 + 2,128 + 875. Nutrien Financial net = 376 − 93. Upstream third-party = 3,571 + 3,807 + 1,660. No subscription or licensing revenue of significance is disclosed.* **Value-chain position.** Nutrien is one of very few companies present from mine and plant gate through to the farm gate. That integration lets it capture producer economics in tight markets (upstream generated about 74% of FY2025 segment adjusted EBITDA) and distribution economics in weak markets (Retail EBITDA is comparatively stable at US$1.4–2.3 billion through the cycle). **Customer types.** **End-markets served:** global grain and oilseed production (the main driver), livestock (Australia), industrial nitrogen (mining, chemicals, diesel exhaust fluid), feed phosphates and industrial phosphoric acid. **Independent characterization.** Nutrien is best understood as a cash-generative, cost-advantaged potash franchise and an efficient North American nitrogen producer, attached to a large, lower-margin but steady distribution business. Pure-play peers cannot replicate the integration, but it has historically weighed on valuation through retail capital intensity, Brazil losses and conglomerate complexity. Under CEO Ken Seitz (since 2022), the company has shifted from growth acquisitions (2018–2022) to portfolio pruning, cost-out and capital returns. The FY2025 results (adjusted EBITDA US$6.05 billion, +13%; free cash flow about US$2.0 billion) and H1 2026 results (adjusted EBITDA US$3.54 billion, +6%) suggest that pivot is gaining traction. The open question is whether the Phosphate review and the 30 November 2026 Investor Day produce a structurally simpler potash–nitrogen–retail company.

Company Headquarters: Deerfield, US Founded: 1946 Workforce: ~3,000 Company Working: CF Industries Holdings, Inc. (CF Industries) a global leader in nitrogen fertilizer manufacturing and distribution. It operates through the following business segments, ammonia, granular urea, urea ammonium nitrate solution (UAN), ammonium nitrate (AN), and others. The others segment includes nitrogen products such as diesel exhaust fluid (DEF), urea liquor, nitric acid, and aqua ammonia. The company produced 10.25 million tons of ammonia as of December 2019. It operates 70 manufacturing plants, out if which 28 are for ammonia, 40 are for UAN, and rest for granular urea.

Company Headquarters: Oslo, Norway Founded: 1905 Workforce: 16,757 Company Working: Yara is the world’s leading fertilizer company and the second-largest producer of ammonia in the world. As a part of its crop nutrition-focused strategy, Yara has simplified its operating model and changed its operating business segments effective from 1 January 2019. The new segment structure is comprised of three segments, namely sales & marketing, new business, and production. The sales & marketing segment includes the crop nutrition, base chemicals, industry reagents, and animal nutrition (excluding South Africa) business units. The “new business” segment includes the environmental solutions, mining applications, animal nutrition - South Africa, and industrial nitrates business units. Under the sales & marketing and the new business segments, the company offers feed acidifiers through the animal nutrition sub-division. Yara has 28 production plants, 200 infrastructure points, and 10,800 Yara-branded retail outlets worldwide. It has production sites in six continents, market operations in more than 60 countries, and sales operations in about 160 countries globally.

Company Headquarters: London, UK Founded: 1971 Workforce: 1,000 Company Working: Sinclair Pharma is a global healthcare company engaged in the development, manufacture, and distribution of pharmaceutical products. Other medical offerings of the company include aesthetics and cosmetic products. It has a portfolio of differentiated complementary aesthetics technologies with a focus on collagen stimulation. The company constitutes a huge network of international distributors throughout the world. Sinclair Pharma operates as a subsidiary of Huadong Medicine Co., Ltd.(China). The company has a strong presence in Europe, as well as the US, Brazil, and South Korea

Company Headquarters: Hyderabad, Telangana, India Founded: 1986 Workforce: 100+ Company Working: Ortin Laboratories Limited is involved in manufacturing and marketing pharmaceutical products and operates through business segments, namely, formulations, API intermediates, research and development, biotechnology, and merchant export trading. The company has its own WHO GMP Standards certified manufacturing unit for the production of raw materials and final products. It recently merged with M/s Vineet Laboratories Pvt. Ltd to expand its product portfolio and gained control over its drug intermediates manufacturing unit. It has a strong presence in India and caters to the needs of government and private customers.

Company Headquarters: Massachusetts, US Founded: 1992 Workforce: ~ 22 Company Working: Yield10 Bioscience, Inc. changed its name from Metabolix Inc. to Yield10 Bioscience, Inc. in 2017. Yield10 Bioscience, Inc. is actively involved in developing and manufacturing high-quality seed traits for the agriculture and food industry. It concentrates on the development of products related to the agricultural bioscience segment in which crops such as corn, soybean, canola, wheat, and rice are main major focus areas of the company. It operates in only one business segment namely, Innovation Platform. Its investments in R&D are significantly high, and it has a strong product pipeline.

| Field | Detail | Source / note | |---|---|---| | Legal name | Evogene Ltd. | Form 20-F FY2025 cover | | Former names | None at parent level identified. Subsidiary Casterra Ag Ltd. was historically linked to the company's castor activity previously associated with "Evofuel Ltd." (Evofuel remains listed as an entity chaired by the CEO) | MarketScreener insider profile; not confirmed as formal rename | | Founded / incorporated | Incorporated 10 October 1999; founders Amir Barzilay and Hagai Karchi; operations commenced as a spin-off from Compugen Ltd. (CEO Ofer Haviv joined from Compugen as CFO in January 2002) | TradingView/CNN profile; 20-F FY2025 (Haviv biography) | | Incorporation jurisdiction | Israel (Israeli Companies Law, 5759-1999) | 20-F FY2025 | | Headquarters | 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel; Tel +972-8-931-1900 | 20-F FY2025 cover | | Exchanges / tickers | Nasdaq Capital Market: EVGN; Tel Aviv Stock Exchange: EVGN | 20-F FY2025 | | Security | Ordinary shares, par value NIS 0.2 (post 1-for-10 reverse split effected 24 July 2024) | 20-F FY2025 | | ISIN | IL0011050551 | TradingView | | CUSIP | n/d | — | | SEC Commission File No. | 001-36187 (foreign private issuer; files 20-F / 6-K) | 6-K August 2026 | | Filer status | Non-accelerated filer; not an emerging growth company | 20-F FY2025 | | Fiscal year end | 31 December | 20-F | | Shares outstanding | 8,718,193 (31 Dec 2025); approx. 12,103,764 (mid-2026, after February 2026 warrant inducement and ATM issuance) | 20-F FY2025; TipRanks (aggregator) | | Employees | 117 (Dec 2024) → 38 (Aug 2026) | Q2 2026 release (via RTTNews) | | Auditor | n/d in sources reviewed for this dossier (historically an Israeli Big-Four affiliate; verify against Item 16C of the FY2025 20-F) | — | | Market capitalisation (current) | Approx. USD 6.6–10.0 million depending on date/price source; at ~USD 0.55 × ~12.1M shares ≈ USD 6.7M | Robinhood (21 Jul 2026: USD 6.59M); Motley Fool (USD 9.99M, undated); PitchBook (15 Jun 2026: USD 6.88M) | | Listing status | Active, dual-listed; Nasdaq minimum-bid-price deficiency (compliance deadline extended to 29 March 2027) | 6-K / PR 30 Sep 2026 | | Dividend | Never paid | Trendlyne / company | The entity profiled is Evogene Ltd., the Israeli computational chemistry company headquartered in Rehovot, Israel, website www.evogene.com. This matches the name and type supplied: it is an active, publicly listed company (dual-listed on Nasdaq and the Tel Aviv Stock Exchange). No alternate entity needed to be substituted. | Metric | FY2023 | FY2024 | FY2025 | Aug-2026 | |---|---|---|---|---| | Employees (headcount, period end) | — | 117 | — | 38 | Aggregators show intermediate figures of 103 and 52, which are consistent with a progressive reduction during 2025–2026 but are not primary-source verified. Evogene is a micro-capitalisation Israeli technology company that has spent 2025–2026 converting itself from a diversified "computational predictive biology" holding group — with subsidiaries spanning ag-biologicals, microbiome therapeutics, castor seeds, ag-chemicals and medical cannabis — into a narrowly focused generative-AI computational chemistry business. Its core asset is ChemPass AI™, a proprietary engine for designing and multi-parameter-optimising novel small molecules for pharmaceutical and crop-protection applications, built in part on a Google Cloud foundation model and now augmented with autonomous AI agents. Monetisation is collaboration-led (upfront, R&D, milestone and royalty economics, with Evogene retaining downstream rights) alongside an internal four-program drug pipeline and an ag-chemical pipeline run through subsidiary AgPlenus. The company has monetised non-core assets (Lavie Bio to ICL; BMC128 licensed to Lishan), cut cash burn by more than half, but remains revenue-light, going-concern-qualified, below Nasdaq's USD 1 bid-price threshold, and embroiled in an activist control contest. --- ### Company's own description In its current corporate boilerplate (press releases from late 2025 onward and the company website), Evogene describes itself as a pioneer in computational chemistry, specialising in the generative design of small molecules for the pharmaceutical and agricultural industries, with ChemPass AI™ — its proprietary generative AI engine — at the core of the offering, designed to produce novel, highly potent molecules optimised across multiple critical parameters, improving success rates while reducing development time and cost. The company labels its operating philosophy "Real-World Innovation", emphasising the integration of computation with industry partner needs (evogene.com/company). The FY2025 20-F still describes the group structure as Evogene acting as a technology hub with divisions and subsidiaries beneath it that draw on the Computational Predictive Biology (CPB) platform and its engines (ChemPass AI and GeneRator AI), each subsidiary being responsible for its own pipeline, go-to-market and financing. However, the same filing makes clear that this hub-and-spoke model has been heavily pruned: Lavie Bio's activity was sold to ICL, Biomica was scaled down to complete one clinical trial, and Casterra and AgPlenus underwent dispositions and workforce reductions. ### Independent characterisation Stripped of legacy framing, Evogene in October 2026 is best characterised as: 1. **An early-stage AI drug-discovery services-and-pipeline company** with six disclosed pharma discovery collaborations (biotechs and academic institutions), no clinical-stage proprietary small molecules, and internal programs at hit-to-lead / lead-optimisation stage. Preclinical work on internal candidates is guided to begin in 2H 2027 (Q2 2026 call). 2. **A small ag-chemical discovery business (AgPlenus)** with one surviving big-ag collaboration (Corteva, herbicides) after Bayer terminated its herbicide project in May 2026, and an internal wheat fungicide program (Zymoseptoria tritici / Septoria) in lead optimisation. 3. **A residual portfolio of monetised or wind-down subsidiaries** — Lavie Bio (asset-sold shell distributing cash), Biomica (licensed BMC128 to Shanghai Lishan; no ongoing operations; reported as discontinued from Q2 2026), and Casterra (castor seeds, realigned exclusively to Brazil). Economically, the company is pre-commercial in its core business. Historical revenue has been dominated by non-core sources — Casterra seed sales and collaboration payments in Lavie Bio and AgPlenus — which are now shrinking or gone. ### Business and revenue model | Revenue stream | Mechanics | Current significance | |---|---|---| | Discovery collaborations (pharma) | Partner brings biology/target; Evogene applies ChemPass AI to generate hits/leads; Evogene retains commercial rights/downstream economics to resulting discoveries | Strategic core; revenue contribution not separately disclosed and appears immaterial to date | | Ag-chemical R&D collaborations (AgPlenus) | Upfront, R&D payments, development milestones, royalties (lower than pure licences) | Historically meaningful (Bayer one-time payment Q1 2024); Bayer project terminated May 2026; Corteva herbicide collaboration continues | | Licensing of assets | Out-licensing of product candidates (e.g., BMC128 to Lishan) with potential future milestones/royalties to subsidiary | Economic value flows via subsidiary dividends (Biomica paid USD 2.7M dividend in Q2 2026; Evogene share ≈ USD 1.35M) | | Product sales | Casterra castor seed sales to industrial (biofuel feedstock) buyers | Largest historical revenue driver in 2024–2025; declined sharply in 2026 | | Asset monetisation | Sale of subsidiaries/tech engines (e.g., Lavie Bio + MicroBoost AI for Ag to ICL) | One-off; recognised in discontinued operations and dividends | | Grants | Israeli Innovation Authority / EU grants netted against R&D | Offsets R&D (e.g., €1.2M EU grant to Ag-Seeds division announced 2024) | Mix characterisation (FY2025, management commentary): the decline in revenue from ~USD 5.6M (restated FY2024) to ~USD 3.9M (FY2025) was attributed to lower AgPlenus milestone revenue, completion of the Corteva collaboration revenue stream recognised in 2024, and lower Casterra seed sales. Product sales (Casterra) therefore made up the majority of FY2025 revenue; licensing/collaboration constituted the balance. No subscription/SaaS revenue exists. ### Value-chain position, customers and end-markets Evogene sits at the very front of the value chain — target-to-hit and hit-to-lead small-molecule discovery — upstream of preclinical development, clinical trials, regulatory approval and commercialisation, all of which it expects partners to carry. In agriculture it sits upstream of formulation, field development, registration (EPA etc.) and distribution, which are controlled by a consolidated oligopoly (Bayer, Corteva, Syngenta, BASF). **Customer types:** biotech companies and academic drug-discovery centres (pharma); multinational crop-protection companies (ag); an industrial castor-seed purchaser (described in filings and calls as a major oil-and-gas company) and seed growers (Casterra). **Customer concentration:** extreme. In H1 2025, one customer (Customer B, Casterra-related) accounted for 63% of revenue, another 14%, and a subsidiary shareholder 11% (6-K, H1 2025 interim statements). In 2021–2023 a single subsidiary shareholder accounted for 35%, 48% and 62% of revenue respectively (20-F FY2023). **End-markets:** AI-enabled small-molecule drug discovery (immunology, neurology, oncology, metabolism per pipeline slide); crop-protection chemicals (herbicides, fungicides); industrial castor oil / biofuel feedstock (Brazil).

Company Headquarters: US Founded: 1992 Workforce: ~10,400 Company Working: Nuance Communications, Inc. develops conversational and cognitive artificial intelligence (AI) solutions. The firm creates software that recognizes, analyses, and responds to people, enhancing human intelligence and boosting productivity and security. Its Healthcare division offers clinical speech and clinical language understanding technologies that help improve the clinical documentation process, from capturing the whole patient record to improving clinical documentation and reimbursement quality standards. dragon medical one, a cloud-based speech solution; computer-assisted physician documentation; diagnostic imaging solutions; Nuance dragon ambient experience, a voice-enabled solution; and clinical documentation enhancement and coding are just a few of the company's offerings. The company offers voice recognition and natural language understanding solutions, which includes automated speech recognition (ASR), natural language understanding (NLU) capabilities, dialog and information management, biometric speaker authentication, text-to-speech (TTS), and optical character recognition (OCR) capabilities. The company's enterprise sector focuses on providing automated customer solutions and services for phone, mobile, web, and messaging channels, particularly employing speech, natural language understanding, and artificial intelligence. Intelligent engagement solutions, conversational AI, engagement AI, and security AI are among the company's offerings. The company's other division offers voicemail transcribing services. healthcare, financial services, telecommunications, government, and retail are among the industries served by the corporation. Nuance Communications, Inc. offers and sells its solutions and technologies through a network of resellers worldwide, including system integrators, independent software vendors, value-added resellers, distributors, hardware vendors, telecommunications carriers, and e-commerce Websites. Microsoft Corporation purchased Nuance Communications for USD 19.7 billion in April 2021, boosting its healthcare position with a pioneer in voice recognition technology. Nuance's technology is used by more than 55 percent of physicians and 75 percent of radiologists in the United States. This acquisition builds on the two companies' current telemedicine collaboration, which began in 2019 and has been accelerated by COVID-19 lockdowns around the world.

Company Headquarters: Indianapolis, US Founded: 1989 Workforce: ~21,100 Company Working: Corteva Agriscience develops, manufactures, and markets a wide range of products, including seeds and traits, crop protection, software, and digital solutions, seed treatments, forages, inoculants, vegetation management, pasture management, turf and ornamental, urban pest management, and oil. It is directly present in more than 50 countries and covers all major regions such as North America, Asia-Pacific, Latin America, Europe, and the Middle East & Africa. Corteva Agriscience is a subsidiary of Dow Chemical Company. Hence, the provided financial information is of the Dow Chemical Company.

Company Headquarters: Petaluma, US Founded: 1993 Workforce: ~2,400 Company Working: LGC Biosearch Technologies operates as a subsidiary of LGC Limited and acquired Douglas Scientific in the year 2016. LGC, Biosearch Technologies designs, manufactures and markets PCR reagents, custom genotyping assays, genomic services, gene editing, and NGS services, as well as workflow solutions. The company operates in three business segments, namely, products, technologies, and services. It is present in more than 22 countries and has seven manufacturing units along with the three service laboratories all over the world. LGC Biosearch Technologies is a subsidiary of LGC Limited. Hence, the provided financial information is of LGC Limited.

Apple is the world's largest consumer technology franchise by revenue and profitability, and — as of mid-August 2026 — the second most valuable listed company globally. Its economic engine is a vertically integrated hardware–silicon–software–services stack anchored on an installed base that surpassed 2.5 billion active devices in the December 2025 quarter. iPhone contributed 50.4% of FY2025 revenue; Services, the highest-margin and fastest-compounding line, contributed 26.2% at a gross margin near 75%. Apple designs its own silicon, controls its operating systems, owns the primary distribution channel for third-party software on its platforms, and outsources substantially all manufacturing. The company is presently navigating three simultaneous inflections: a CEO succession (John Ternus replaces Tim Cook on 1 September 2026), a strategic pivot in artificial intelligence executed through a licensing partnership with Google's Gemini, and an acute global memory-component shortage that management has characterised as a once-in-a-century pricing event. --- **The company's own characterisation.** Apple's FY2025 Form 10-K describes the business as designing, manufacturing and marketing smartphones, personal computers, tablets, wearables and accessories, and selling a range of related services. It identifies six software platforms — iOS, iPadOS, macOS, watchOS, visionOS and tvOS — as providing consistent experiences across devices, and lists services spanning advertising, AppleCare, cloud, digital content and payments. The 10-K states that the company's customers are primarily in the consumer, small and mid-sized business, education, enterprise and government markets, and that it sells through both direct channels (its own retail and online stores and direct sales force) and indirect channels (third-party cellular carriers, wholesalers, retailers and resellers). During FY2025 the direct/indirect split of net sales was 40%/60%. **Independent characterisation.** Apple operates a closed-loop platform business disguised as a hardware manufacturer. The correct way to model it is as a two-stage machine. *Stage one — installed-base acquisition.* Hardware is sold at gross margins that, while high for consumer electronics, are the lower-margin half of the business. Products gross margin ran at approximately 38.7% in Q2 FY2026 versus 76.7% for Services (management commentary, Q2 FY2026 earnings call). Hardware's strategic function is to install and renew an addressable base. That base exceeded 2.5 billion active devices as of the December 2025 quarter, up from 2.35 billion a year earlier. *Stage two — monetisation of the base.* Services extract recurring, capital-light, near-software-margin revenue from that base through seven identified streams: advertising, AppleCare, cloud services, digital content (App Store and Apple's own subscription properties), payment services, and licensing. Cumulative paid subscriptions across Apple's platforms and third-party App Store subscriptions surpassed 1.5 billion as of Q3 FY2026 — roughly three years after crossing 1 billion. **Revenue model mix (FY2025).** Product sales 73.8% ($307,003M); Services 26.2% ($109,158M). Within Services, a material but undisclosed component is licensing revenue from Google for default search placement in Safari — estimated at approximately $20 billion in 2022 per unsealed exhibits in *United States v. Google LLC*, which would have represented roughly one-fifth of FY2024 Services revenue. Apple does not disclose this figure. It is the single largest identified concentration risk inside the Services line. **Value chain position.** Apple occupies the design, silicon architecture, operating system, brand, and retail distribution layers, and has increasingly extended into the component layer through in-house silicon (A-series, M-series, C-series modems, N-series networking). It does not own volume assembly; substantially all manufacturing is performed by outsourcing partners, principally in China, India and Vietnam. It is a price-setter in premium smartphones and a price-taker in memory — a structural asymmetry that became the dominant financial story of 2026. **Customer types and end-markets.** Consumer (dominant), small and mid-sized business, education, enterprise, government and healthcare. Apple maintains dedicated go-to-market programmes for business, education, healthcare and government, but does not disclose revenue by customer type.

Company Headquarters: Paris, France Founded: 1990 Workforce: ~ 6,653 Company Working: Vilmorin & Cie is one of the world’s leading companies in the seed sector. The company has three business segments, namely, vegetable seeds, field seeds, and garden seeds activity, and out of these vegetable and field seeds are its core businesses. It relies on continuous investment in its research and development (R&D) and a robust international development strategy to strengthen its position in the market. It also focuses exclusively on seeds and is not at all involved in agrochemicals.

Company Headquarters: Plano, Texas, US Founded: 1981 Workforce: ~155,000 Company Working: Keurig Dr Pepper is a global leader in manufacturing beverages. The company offers different products such as flavored (non-cola) carbonated soft drinks (CSDs) and non-carbonated beverages (NCBs), including ready-to-drink teas and coffee, juices, water, mixers, and specialty coffee. It has a strong presence and a production facility in the US. It offers more than 125 brands of different products.

Company Headquarters: Midland, US Founded: 1883 Workforce: ~98,000 Company Working: DowDuPont is a holding company that develops agricultural products, specialty materials, and chemicals. It operates through 534 manufacturing sites and the agriculture, performance materials and coatings, industrial intermediates and infrastructure, packaging and specialty plastics, electronics and imaging, nutrition and biosciences, transportation and advanced polymers, and safety and construction segments. DowDuPont planned to create three independent companies called Corteva Agriscience, Dow, and New DuPont, where Covetra Agriscience will represent the agriculture division of the company, while Dow will represent the materials science division, and New DuPont the specialty products division. In April 2019, DowDuPont completed separation of materials science division through the spin-off of Dow Inc and is likely to complete the separation of its agriculture division in June 2019.

Company Headquarters: California, US Founded: 2002 Workforce: ~40 Company Working: Arcadia Biosciences develops and markets high-value food ingredients, nutritional oils, and improved crops using biotechnology techniques. This consumer-driven agricultural technology company uses state-of-the-art gene-editing technology and advanced breeding techniques to naturally enhance the nutritional quality of grains and oilseeds to address the rapidly evolving trends in consumer health and nutrition. The company has also developed a broad pipeline of high-value crop productivity traits designed to enhance farm economics. It provides gamma-linolenic acid safflower (Carthamus tinctorius) oil under the brand SONOVA. It has collaboration with Dow AgroSciences LLC to develop and commercialize soybean traits. Based in Davis, it comprises administrative offices in Phoenix and Arizona in the US. Some of the flagship brands of Arcadia Biosciences include GoodWheat, SONOVA, and HB4, among others. The company’s portfolio of agricultural traits (Nitrogen Use Efficiency, Salinity Tolerance, Water Use Efficiency) is being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. As of March 2019, the company’s patent portfolio included 153 issued patents and 63 pending patent applications worldwide in 30 patent families relating to the trait technologies. This company, along with Bioceres Crop Solutions Corp. also constitutes a joint venture, Verdeca, which is focused on developing and deregulating crop varieties with next-generation agricultural technologies. Verdeca received commercialization approval from the US Food and Drug Administration (FDA) in 2017 for HB4 Drought Tolerance trait in soybean. Regulatory approvals for the same product were obtained in Argentina in 2015. Regulatory submissions were made in 2016 for import approval of HB4 soybeans into China, whereas regulatory approval for Brazil was submitted in 2018, and import approval in the European Union is to be submitted in 2019.

LANXESS is a mid-cap German specialty chemicals group. It was carved out of Bayer in 2004 and over two decades has transformed from a cyclical rubber- and plastics-heavy portfolio into a three-segment specialty chemicals company: Consumer Protection, Specialty Additives and Advanced Intermediates. The transformation has been completed in sequence. The rubber exit came via ARLANXEO (2016–2018). Engineering plastics were contributed to the Envalior joint venture (2023). Urethane Systems was sold to UBE (April 2025). LANXESS now describes itself as a pure specialty-chemicals provider. The group holds globally relevant positions in several niches: - bromine-based flame retardants - biocides and material protection - benzoic acid and benzoate derivatives - ion-exchange resins (Lewatit) - iron-oxide pigments (Bayferrox) - lubricant and rubber additives - aromatic intermediates for agrochemicals The investment case today is a deleveraging and self-help story. FY2025 sales were EUR 5.67bn and EBITDA pre was EUR 510m. Net debt is about 4x EBITDA pre, and the rating is sub-investment-grade at Moody's. The equity value is now comparable to the book value of LANXESS's 40.94% Envalior stake. Value realisation hinges on the Envalior exit (2027/2028), EUR 150m of structural cost savings and a European chemicals recovery. --- ### What the company does LANXESS develops, manufactures and markets three groups of products: - chemical intermediates (aromatics, amines, nitro and chlorinated aromatics, inorganic pigments) - additives (flame retardants, plasticisers, lubricant additives, rubber chemicals) - consumer protection products (biocides, disinfectants, preservatives, aroma chemicals, benzoates, ion-exchange resins, custom synthesis) Following the April 2025 Urethane Systems sale, the group reports three segments: Consumer Protection (CP), Specialty Additives (SA) and Advanced Intermediates (AI). It also holds a 40.94% equity-accounted stake in Envalior, the engineering-materials joint venture with Advent International. **Company's own description (paraphrased from corporate boilerplate and the 2024 Annual Report).** LANXESS describes itself as a leading specialty chemicals company whose core business is the development, manufacturing and marketing of chemical intermediates, additives and consumer protection products. It operates in around 32 countries. ### Business model and revenue model | Revenue model element | Characterisation | |---|---| | Product vs. service mix | Close to 100% product sales (B2B chemical products sold by weight or volume). Service-like revenue is limited to custom manufacturing (toll and exclusive synthesis at Saltigo) and application and technical support bundled with products. | | Subscription / licensing | Not material; no licensing revenue is disclosed | | Contracting | Mix of annual and multi-year supply agreements (agro intermediates, custom synthesis) and spot or quarterly pricing (commodity-linked intermediates, pigments). Raw-material and energy pass-through clauses apply in parts of the portfolio. | | Pricing model | Cost-plus with indexation in intermediates. Value-based pricing in specialties (biocides, flame retardants, ion-exchange resins). Periodic list-price increases, e.g. a 6–8% increase on Lewatit resins in spring 2026. | ### Value-chain position LANXESS sits mid-chain. It buys petrochemical feedstocks (benzene, toluene, chlorine, ammonia, cyclohexane) and minerals (bromine brines at El Dorado, Arkansas; iron sources for pigments). It converts these into intermediates and functional additives that customers formulate into their own end products. These customers include agrochemical majors, coatings and construction-materials producers, plastics compounders, lubricant blenders, tyre makers, and personal-care and household brands. A significant share of Advanced Intermediates output is captive or quasi-captive: it feeds downstream LANXESS units (Saltigo, MPP, Polymer Additives) in integrated German Verbund sites at Leverkusen, Krefeld-Uerdingen and Dormagen. ### Customer types and end-markets | End-market | Exposure (qualitative) | Comment | |---|---|---| | Agrochemicals | High (Saltigo, AII aromatic intermediates, MPP actives) | Agro is about 70–80% of Saltigo sales (Q2 2026 call). Generic agro is under Chinese and Indian price pressure. | | Construction | High (Bayferrox pigments, flame retardants, plasticisers, biocides for paints) | The company expects a construction recovery in 2027 and has removed construction upside from its 2026 guidance | | Automotive / transport | Medium (lubricant additives, rubber chemicals, AII products) | Reduced to approx. 10% of revenues after the Envalior carve-out (investor estimate, MOI Global 2024) | | Consumer / personal care / household | Medium (benzoates, aroma chemicals, preservatives, disinfectants) | Most defensive pocket; CP margins rose to 15.4% in FY2025 | | Water treatment / energy / food | Medium (Lewatit ion-exchange resins) | Structural growth niche | | Pharma / specialty / electronics | Low but targeted (Saltigo pivot) | Management sees these as higher-margin growth markets for Saltigo | | Electronics, E&E, plastics (flame retardants) | Medium | Bromine and phosphorus flame retardants | The company has repeatedly identified agrochemicals, construction and automotive as the end-markets that drove the 2023–2025 downturn. The CEO's comment on Q3 2025 named these three as the most difficult. **Independent characterisation.** Despite the "specialty" label, LANXESS is in practice a hybrid. Roughly 40% of sales (Consumer Protection plus parts of Specialty Additives) behave like true specialties, with pricing power, low capital intensity and 13–16% margins. Roughly 30% (Advanced Intermediates) remains a scale- and energy-intensive commodity-to-semi-specialty business that is exposed to Asian overcapacity and German energy costs. The group's EBITDA margin pre exceptionals has compressed from 13.4% (FY2021, continuing operations) to 9.0% (FY2025). This is well below specialty peers and is the core reason for the de-rating.

Company Headquarters: Vevey, Switzerland Founded: 1905 Workforce: 328,000 + employees (2017) Company Working: The company is focusing on developing the world's best products and services for all stages of life helping people and their families. The company produces approximately a billion science-based nutritional solutions per year which are available through retail and pharmacy outlets or recommended by healthcare professionals in institutions, which addresses a spectrum of health conditions from pediatric allergy to malnutrition amongst the frail elderly.

Company Headquarters: Dublin, Ireland Founded: 2013 Workforce: ~16,900 Company Working: Allergan is a leading global pharmaceutical company. The company is engaged in the manufacturing and commercialization of hyaluronic acid for medical products, devices, biologics, and surgical products for patients across the world. It operates through three business segments, namely US Specialized Therapeutics, US General Medicine, and International. The company sells its products primarily to the retailers and distributors including food store chains and national retail drug. The prime customers are hospitals, clinics, and government agencies as well as managed healthcare providers, such as health maintenance organizations and other institutions. The company has operations in 100 countries. The US and Canada account for around 10% of the company’s revenue. The three prominent customers of the company are McKesson Corporation, which accounted for around 25% of the sales revenue; Cardinal Health, Inc with 23%; and AmerisourceBergen Corporation with 22% in 2018. In addition, the company has development and manufacturing centers of raw materials, intermediate ingredients, and active pharmaceutical ingredients. Its manufacturing plants are located in Ireland, the US, Brazil, Belgium, France, and Costa Rica.

Company Headquarters: Warsaw, Indiana, (US) Founded: 1927 Workforce: 19,000+ Company Working: Zimmer develops, produces, and markets musculoskeletal healthcare products. It is a leading brand in providing customized joint and bone healthcare solutions. It offers products related to orthopedics, healthcare, medical instruments, medical technology, surgical instruments, medical supplies, medical devices, innovation, and signature solutions. The company is present in all major markets and holds significant market share in the global tissue engineering market.

Company Headquarters: Tokyo, Japan Founded: 1939 Workforce: ~10,476 Company Working: Showa Denko KK is a chemical company that engages in the manufacturing and marketing of a wide range of petrochemicals, chemicals, electronics, inorganic chemicals, aluminum, and other products. The company, along with its affiliates and subsidiaries, operates in North America, Europe, and Asia. It provides products and services that are useful and exceed customer expectation.

Company Headquarters: San Diego, California, US Founded: 2011 Workforce: ~214 Company Working: Retrophin, Inc., is a biopharmaceutical company that develops and delivers therapies for people with rare diseases. It operates in different therapeutic areas such as fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), and other life-threatening neurological disorders. The company focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases.